Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial

Tufia C. Haddad; Vera J. Suman; Karthik V. Giridhar; Kostandinos Sideras; Donald W. Northfelt; Brenda Ernst; Ciara C. O’Sullivan; Ravinder J. Singh; Zeruesenay Desta; Prema P. Peethambaram; Timothy J. Hobday; Saranya Chumsri; Roberto A. Leon‐Ferre; Kathryn J. Ruddy; Siddhartha Yadav; Jodi L. Taraba; Barbara Goodnature; Matthew P. Goetz; Liewei Wang; James N. Ingle

doi:10.1158/1078-0432.26422919.v1

Abstract

Supplemental Table 2: All adverse events among those patients who discontinued ANA1 early or did not continue onto ANA10 after IES finding due to toxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Haddad et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574ec9 https://doi.org/10.1158/1078-0432.26422919.v1

View Full Paper

Ask AI

Bookmark

Share

Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial

Abstract

Discussion

Cite This Study

Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading